Scarica l'app Stockscreener
15.24
0.23%
-0.035
Dopo l'orario di chiusura:
15.25
0.005
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Precedente Chiudi:
$15.28
Aprire:
$15.42
Volume 24 ore:
47,102
Relative Volume:
0.81
Capitalizzazione di mercato:
$107.07M
Reddito:
$100.44M
Utile/perdita netta:
$-133.16M
Rapporto P/E:
-0.5918
EPS:
-25.76
Flusso di cassa netto:
$-94.85M
1 W Prestazione:
-5.19%
1M Prestazione:
+32.45%
6M Prestazione:
+161.04%
1 anno Prestazione:
+65.71%
Intervallo 1D:
$14.92
$16.28
Intervallo di 1 settimana:
$14.00
$16.28
Portata 52W:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Nome
Atara Biotherapeutics Inc
Settore
Industria
Telefono
805-623-4211
Indirizzo
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Confronta ATRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
15.24 | 102.61M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-09 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-20 | Downgrade | Citigroup | Neutral → Sell |
| 2022-07-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2021-05-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Iniziato | Evercore ISI | Outperform |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-23 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Downgrade | Goldman | Neutral → Sell |
| 2019-09-16 | Downgrade | Jefferies | Buy → Hold |
| 2019-06-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2019-05-30 | Iniziato | ROTH Capital | Buy |
| 2019-05-23 | Iniziato | Stifel | Buy |
| 2019-01-23 | Iniziato | Mizuho | Buy |
| 2018-04-10 | Iniziato | JP Morgan | Overweight |
| 2018-03-16 | Iniziato | Guggenheim | Neutral |
| 2018-03-05 | Reiterato | Jefferies | Buy |
| 2018-02-28 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Downgrade | Citigroup | Neutral → Sell |
| 2018-01-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
Volume spikes in Atara Biotherapeutics Inc. stock – what they meanPortfolio Growth Summary & Daily Growth Stock Tips - newser.com
How to use Fibonacci retracement on Atara Biotherapeutics Inc.Forecast Cut & Fast Exit/Entry Strategy Plans - newser.com
What institutional flow reveals about Atara Biotherapeutics Inc.2025 Market Outlook & Momentum Based Trading Signals - newser.com
How to escape a deep drawdown in Atara Biotherapeutics Inc.July 2025 Setups & AI Powered Market Entry Ideas - newser.com
Will Atara Biotherapeutics Inc. stock maintain growth storyJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com
How Atara Biotherapeutics Inc. stock reacts to global recession fearsJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Can you recover from losses in Atara Biotherapeutics Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Chart based exit strategy for Atara Biotherapeutics Inc.Market Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Using economic indicators to assess Atara Biotherapeutics Inc. potentialJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Will Atara Biotherapeutics Inc. continue its uptrendWeekly Risk Summary & Precise Buy Zone Tips - newser.com
What hedge fund activity signals for Atara Biotherapeutics Inc. stockJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
How rising interest rates impact Atara Biotherapeutics Inc. stockRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Atara Biotherapeutics' (ATRA) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry - simplywall.st
Atara Biotherapeutics Inc. stock trendline breakdownQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Statistical indicators supporting Atara Biotherapeutics Inc.’s strengthJuly 2025 Rallies & Verified Momentum Stock Ideas - newser.com
Pattern recognition hints at Atara Biotherapeutics Inc. upside2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Atara Biotherapeutics Inc Stock Analysis and ForecastAutomated Trading Signals & Your Free Entry to Smart Investing Starts Here - earlytimes.in
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Price Target from Brokerages - Defense World
How Atara Biotherapeutics Inc. (AT20) stock stacks up against competitorsNew Guidance & Real-Time Market Trend Scan - newser.com
Is Atara Biotherapeutics Inc. stock positioned for long term growthPortfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
What drives Atara Biotherapeutics Inc stock priceStock Price Divergence & Low Entry Capital Stocks - earlytimes.in
Can swing trading help recover from Atara Biotherapeutics Inc. losses2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
Analyzing net buyer seller activity in Atara Biotherapeutics Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - newser.com
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - inkl
Atara Biotherapeutics Inc Azioni (ATRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Atara Biotherapeutics Inc Azioni (ATRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):